Top Medical News
Diabetic retinopathy predicts heart problems in type 1 diabetes
2 days ago
Among individuals with type 1 diabetes, diabetic retinopathy is independently associated with prevalent and incident cardiovascular disease, as reported in a study.
Low sexual function scores tied to arterial stiffness in postmenopausal women
3 days ago
Lower scores of sexual function in postmenopausal women are predictive of weakened vascular function, as manifested by arterial stiffening, which then contributes to systolic blood pressure (SBP) changes, according to a recent study.
Breastfeeding delivers long-term cardiometabolic benefits in offspring
Audrey Abella, 3 days ago
In a secondary analysis of the HAPO FUS*, breastfeeding was found to be associated with lower rate of glucose metabolism disorders in the offspring; however, this association was not seen among the mothers.
Quitting smoking in pregnancy tied to weight gain and high HDP risk, but lower stillbirth risk
4 days ago
Smoking discontinuation during pregnancy is associated with both positive and negative outcomes, such as reduced risk of stillbirth but higher risk of hypertensive disorders of pregnancy (HDP) and weight gain, according to a study.
Pitavastatin reduces noncalcified plaque in people with HIV at low-to-moderate CVD risk
5 days ago
In people living with HIV (PWH) who are at low-to-moderate risk of cardiovascular disease (CVD), use of pitavastatin for 2 years leads to a reduction in noncalcified plaque volume and progression, which potentially contributes to a decrease in major adverse cardiovascular events (MACE), according to the results of the mechanistic substudy of the REPRIEVE trial.
Apixaban recommended for blood clot prevention in gynaecologic cancer surgery
5 days ago
Prophylactic apixaban appears to effectively reduce the risk of venous thromboembolism (VTE) for patients undergoing open surgery for gynaecologic malignancies and should be considered the standard of care for VTE prophylaxis in this population, according to a retrospective study.
Severe OSA in IHD patients ups AF risk during sleep
Elaine Soliven, 6 days ago

Severe obstructive sleep apnoea (OSA) in patients with ischaemic heart disease (IHD) is associated with an increased risk of atrial fibrillation (AF) during sleep, according to a Singapore study.

Special Reports
fenofibrate, metabolic syndrome, statins, omega-3 fatty acids, MACE
05 Feb 2024
A nationwide population-based cohort study in South Korea compared the effectiveness of omega-3 fatty acids and fenofibrate for reducing major adverse cardiovascular events (MACE) in individuals with metabolic syndrome (≥30 years) on statin therapy.1
Treating type 2 diabetes mellitus with G.R.A.C.E.
22 Jan 2024
A challenging aspect of glycaemic control presents in patients diagnosed with early-onset type 2 diabetes mellitus (T2DM). Considering this challenge, how can effective management of glycaemic control be achieved in patients with uncontrolled T2DM who are hesitant to incorporate multiple oral antidiabetic drugs into their current regimen? In this case study, Dr Matthew Tan shared his clinical experience in managing a young adult patient with T2DM using GLYXAMBI®, a fixed-dose combination of empagliflozin and linagliptin taken once daily. He demonstrated how applying the G.R.A.C.E. concept to the treatment improved the patient’s clinical outcome.

This advertorial is sponsored as an educational programme by Boehringer Ingelheim Singapore Pte. Ltd.
Optimisation of glycemic control with empagliflozin/linagliptin combination in a patient with type 2 diabetes mellitus uncont
30 Nov 2023
Data has demonstrated the efficiency of utilizing a combination of empagliflozin and linagliptin to effectively manage glycemic levels in patients with Type 2 diabetes (T2D) who are uncontrolled on metformin. In this retrospective analysis, we examine the combination of empagliflozin and linagliptin added to existing combination of multiple glucose-lowering medications sans insulin, which revealed significant improvements in both glycemic and cardio-renal outcomes for adults with T2D. This combination therapy was well-tolerated and showed promising clinical effectiveness when used in combination with commonly prescribed antidiabetic drugs for patients with inadequately controlled diabetes.

Sponsored as an educational program by Boehringer Ingelheim Singapore Pte. Ltd.
Effective management of type 2 diabetes mellitus with a combination of metformin and empagliflozin in a patient with metaboli
01 Nov 2023
Metabolic Syndrome (MS) is linked to insulin resistance and a combination of five medical conditions that increase the risk of developing atherosclerotic cardiovascular disease (ASCVD). Obesity is independently associated with an increased incidence of diabetes mellitus, hypertension, hyperlipidemia, cardiovascular disease (CVD), and certain cancers. Early CVD protection is crucial in MS patients with Type 2 diabetes (T2DM). The use of empagliflozin/metformin for managing T2DM in MS improved fasting blood glucose levels and HbA1c, demonstrating the effectiveness of this combination in both ASCVD and CVD risk factors patients.

Sponsored as an educational program by Boehringer Ingelheim Singapore Pte. Ltd.
Oral anticoagulant therapy for acute VTE in obese patients
Adjunct Assistant Prof. Pankaj Kumar Handa, 03 Apr 2023
Although direct-acting oral anticoagulants (DOACs) are widely recommended for first-line treatment of venous thromboembolism (VTE), their use in obese patients remains controversial due to the limited representation of such patients in clinical trials. As the prevalence of obesity continues its upward trend, clinicians increasingly have to make treatment decisions for obese patients. MIMS Doctor interviewed Adjunct Assistant Professor Pankaj Kumar Handa, Senior Consultant at Tan Tock Seng Hospital, Singapore, to gain his perspectives on oral anticoagulation in obese patients.
EMPULSE trial confirms the efficacy and safety profile of empagliflozin in patients stabilized in hospital following acute he
21 Mar 2023
Empagliflozin is the first SGLT-2i to significantly improve outcomes for patients with HF in any setting (in-hospital/outpatient), across the full spectrum of HF. Results from the EMPULSE trial showed that patients hospitalized for acute HF who were treated with empagliflozin following stabilization had 36% clinical benefit on the composite of mortality, HF events, and KCCQ-TSS improvement. The EMPULSE trial also provides a reassuring safety profile for empagliflozin that is consistent with previous trials.
NCDs in Focus Act Now! Summit 2022
16 Mar 2023

Viatris, a global healthcare company, collaborated with the Thai Hypertension Society and the Thai NCD Collaboration Group to organize the NCDs in Focus Act Now! Summit 2022 in Bangkok on October 29th and 30th. This summit brought together nearly 300 multidisciplinary experts from Southeast Asia and India to address the unmet needs in managing two critical noncommunicable diseases (NCDs): cardiovascular diseases (CVDs) and mental health disorders (MHDs) in the region.

The summit had several key objectives. Firstly, it highlighted the effectiveness of clinical data in addressing gaps and unmet needs in clinical practice. Secondly, it emphasized the importance of sharing expertise and best practices through a platform that can optimize patient care. Additionally, it discussed the challenges of cardiovascular disease and mental health disorder care in a post COVID-19 world, and the need to re-examine them.

The summit also offered valuable insights into policy and practice changes, as well as innovative digital solutions that can lead to better outcomes. Lastly, it emphasized the significance of gaining a deeper understanding of the gaps in the patient journey to enhance patient care further.

Overall, the NCDs in Focus Act Now! Summit 2022 was a highly informative and productive event, with experts collaborating to improve the management of CVDs and MHDs in Southeast Asia and India.

Conference Reports
Add-on PCSK9 inhibitor cuts LDL-C by half, allows infrequent dosing in patients maxed out on statins
Elvira Manzano, 19 Dec 2023
Injection with the novel, long-acting PCSK9 inhibitor recaticimab once every 3 months reduces LDL-cholesterol (LDL-C) levels by >50 percent compared with placebo in patients already maxed out on statins in the phase III REMAIN-2 trial.
AI-guided stethoscope helps detect cardiomyopathy during pregnancy
Elvira Manzano, 18 Dec 2023
A screening programme that incorporates artificial intelligence (AI)-guided digital stethoscope improves clinicians’ ability to detect peripartum cardiomyopathy in the Nigerian SPEC-AI trial.
Add-on recaticimab cuts bad cholesterol in non-FH, mixed hyperlipidaemia patients
Audrey Abella, 05 Dec 2023
In the phase III REMAIN-2 trial, add-on recaticimab – a novel, long-acting anti-PCSK9 monoclonal antibody (mAb) – led to reductions in bad cholesterol and other lipids in patients with non-familial hypercholesterolaemia (non-FH) and mixed hyperlipidaemia inadequately controlled on background statin therapy.
Some signal of benefit found for liberal transfusion strategy for anaemic heart attack patients
Jairia Dela Cruz, 28 Nov 2023
Adopting a liberal blood transfusion strategy in patients with acute myocardial infarction (AMI) and anaemia does not appear to do much in terms of reducing the risk of AMI recurrence or death compared with a restrictive transfusion strategy, although there appears to be a hint of benefit, as shown in the results of the phase III MINT trial.
Self-monitored BP bests clinic readings in hypertension management
Jairia Dela Cruz, 27 Nov 2023
Empowering mums to self-monitor their blood pressure (BP) with a physician-guided titration of antihypertensive medications helps lower postpartum BP level after a pregnancy complicated by hypertension, as shown in the POP-HT trial.
Favourable long-term results with zotarolimus-eluting stents in CTO
Elvira Manzano, 25 Nov 2023
An ultrathin stent performed just as well as the conventional thin-strut stent in patients at high risk of bleeding in the first head-to-head COMPARE 60/80 trial, providing a new and effective drug-eluting stent (DES) option.
Intensive BP-lowering reduces dementia risk in patients with hypertension
Elaine Soliven, 23 Nov 2023

Among Chinese patients with hypertension, a 48-month intensive blood pressure (BP) intervention programme significantly reduces the risk of developing dementia than usual care, according to a study presented at AHA 2023.